Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Drug Res (Stuttg) ; 74(6): 290-295, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38968952

ABSTRACT

BACKGROUND: There have been reports of serious side effects of Remdesivir, including cardiovascular complications. The present study aimed to determine the adverse cardiovascular effects of Remdesivir and the factors affecting them in COVID-19 patients. METHODS: The patients were classified into two groups: those receiving Remdesivir without cardiac complications and those receiving Remdesivir with cardiovascular complications. After reviewing the patient's medical records, the relationship of some factors with the incidence of adverse cardiovascular effects was measured. RESULTS: Chi-square test showed that the distribution of complications in men was significantly higher than in women (P=0.001). The independent t-test revealed that the mean age in the group with complications was significantly higher than the group without complications (P=0.013). Fisher's exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in the groups with and without heart complications. CONCLUSION: Our findings indicated that most of the COVID-19 patients suffered from sinus bradycardia, and the distribution of complications was more pronounced in men than in women. The mean age in the group with complications was higher than the group without complications. Smoking was found to be associated with the occurrence of cardiovascular complications and the mean changes of Bilirubin and ALKP before and after treatment were significantly different in the groups with and without cardiovascular complications.


Subject(s)
Adenosine Monophosphate , Alanine , Antiviral Agents , COVID-19 Drug Treatment , COVID-19 , Humans , Male , Alanine/analogs & derivatives , Alanine/adverse effects , Alanine/therapeutic use , Female , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/adverse effects , Adenosine Monophosphate/therapeutic use , Middle Aged , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , Case-Control Studies , Aged , COVID-19/complications , Adult , SARS-CoV-2 , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/epidemiology , Sex Factors , Bradycardia/chemically induced , Bradycardia/epidemiology , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL